Prescribing Information & Medication Guide

This site is intended for US healthcare professionals.
For patients and other support inquiries, call 1-844-454-KITE.

Welcome to Kite Konnect

Kite Konnect™ is committed to helping patients and healthcare teams throughout YESCARTA™ (axicabtagene ciloleucel) treatment.

YESCARTA™ is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. 

Limitation of Use: YESCARTA™ is not indicated for the treatment of patients with primary central nervous system lymphoma. 

Patient Enrollment

Hospital Portal access, Cell Order completion, and leukapheresis scheduling

Reimbursement Support

Benefits investigation, claims appeals, and support for eligible uninsured and underinsured patients

Logistics Support

Connecting patients with independent foundations to help with transportation and housing

Ongoing Commitment

Cell Order tracking and continuous communication

YESCARTA (axicabtagene ciloleucel) is available only at authorized treatment centers

See a list of authorized treatment centers »



Enroll a YESCARTA Patient

To get your patient started with YESCARTA™, please enroll your patient using the Kite Konnect™ Hospital Portal.

Initiate YESCARTA Leukapheresis

If you are ready to initiate leukapheresis, please use the Kite Konnect™ Apheresis Collection App (Vineti Application).

Go to Vineti Application

Currently authorized treatment centers

Centers listed alphabetically by state